Skip to content
Buy This GLP
← Research
Evidence

Is Liraglutide as Good as Semaglutide for Weight Loss? 6.4% Against 15.8%

In STEP 8, average weight loss was 6.4% with liraglutide and 15.8% with semaglutide. More participants stopped liraglutide because of adverse events.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Weight lost at 68 weeks, STEP 8semaglutide 2.4 mg15.8%liraglutide 3.0 mg6.4%placebo1.9%338 adults without diabetes

STEP 8 directly compared two injection regimens in 338 adults without diabetes [1]. When reading about weight loss across GLP-1 trials, check which drug, dose and follow-up each study used.

Weight loss at 68 weeks

Mean weight change was −15.8% with weekly semaglutide 2.4 mg and −6.4% with daily liraglutide 3.0 mg [1]. The difference was −9.4 percentage points (95% CI −12.0 to −6.8). All groups received counseling on diet and physical activity.

At least 10% weight loss was reached by 70.9% on semaglutide and 25.6% on liraglutide. The active comparison was open-label, so participants knew which of the two drugs they received.

Digestive effects and stopping treatment

Digestive adverse events affected 84.1% on semaglutide and 82.7% on liraglutide [1]. Adverse events led to stopping treatment for 3.2% and 12.6%, respectively. The figures for stopping for any reason were 13.5% and 27.6%, respectively.

Studies of why people stop GLP-1 treatment outside trials include factors such as cost and access. STEP 8 compared tolerability under trial conditions.

What a Greek payer model adds

A 68-week Greek model estimated that semaglutide cost the payer more per course [2]. It estimated a lower cost per patient reaching 5% weight loss: €3,768.72 with semaglutide and €4,718.66 with liraglutide. These figures depend on local prices and the chosen weight-loss threshold.

Frequently asked

Which drug produced more weight loss in STEP 8?
Semaglutide. At 68 weeks, average weight loss was 15.8% with semaglutide and 6.4% with liraglutide.
How did side effects compare?
Digestive issues were common with both. Adverse events led to stopping in 3.2% of the semaglutide group and 12.6% of the liraglutide group.
Which drug cost less in the Greek payer model?
Liraglutide cost less per treatment course. Semaglutide cost less per patient reaching the 5% weight-loss target in the model.

Sources

  1. [1] Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial JAMA. PMID 35015037
  2. [2] Papantoniou P, Maniadakis N (2025). Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis PharmacoEconomics - Open. PMID 39847271

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence